HR Execs on the Move

Health Decisions

www.HealthDec.com

 
Health Decisions (www.HealthDec.com) is a global clinical research organization (CRO) committed to helping drug and device companies achieve greater success. Our sponsors rely on us to help them prove the value of their pipelines both faster and with the smartest possible allocation of funds. Through Agile Clinical Development- a strategic combination of adaptive design and adaptive operations Health Decisions optimizes every facet of clinical research from design protocol to the most detailed day-to-day management, so sponsors can make the most of competitive market opportunities.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.HealthDec.com
  • 6350 Quadrangle Dr Ste 300
    Chapel Hill, NC USA 27517
  • Phone: 919.967.1111

Executives

Name Title Contact Details

Similar Companies

Tracy Anderson

Tracy Anderson is the leader of the health and wellness industry and Creator of the Tracy Anderson Method, offering fitness DVDs, online workouts, state-of-the-art exercise studios, nutritional products, apparel and more.

EsferaMed International

EsferaMed International is a Scottsdale, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Xtant Medical

Xtant Medical (NYSE MKT: XTNT) develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. With core competencies in both biologic and non-biologic surgical technologies, Xtant can leverage its resources to successfully compete in global neurological and orthopedic surgery markets.

T3D Therapeutics

T3D Therapeutics` mission is to develop its lead drug product candidate, T3D-959, as a potential `First-in-Class`and `Best-in-Class` disease-modifying, breakthrough medicine for the treatment of Alzheimer`s disease with the potential to slow, stop or reverse the course of the disease. The Company is also seeking to maximize the therapeutic utility of T3D=959 and has initiated pre-clinical studies in Huntington’s Disease models.